Ocular Therapeutix
Logotype for Ocular Therapeutix Inc

Ocular Therapeutix (OCUL) investor relations material

Ocular Therapeutix Q1 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Ocular Therapeutix Inc
Q1 2026 earnings summary5 May, 2026

Executive summary

  • SOL-1 trial demonstrated AXPAXLI's statistical superiority over approved anti-VEGF in wet AMD, with unmatched durability and disease control, maintaining vision in two-thirds of patients for a year with a single injection.

  • SOL-X long-term extension trial initiated to evaluate AXPAXLI's outcomes over five years; SOL-R non-inferiority trial fully enrolled with topline data expected Q1 2027.

  • HELIOS-3 Phase 3 trial in diabetic retinopathy ongoing, aiming for a broad label across diabetic retinal disease.

  • AXPAXLI showed a strong safety profile with no treatment-related serious ocular or systemic adverse events.

  • Commercial readiness is being accelerated, with infrastructure, payer engagement, and strategy refinement underway for a potential major retina therapy launch.

Financial highlights

  • Ended Q1 2026 with $666.7 million in cash and cash equivalents, providing runway into 2028 and flexibility to advance NDA submission, complete ongoing trials, and accelerate commercial readiness.

  • Net product revenue for Q1 2026 was $10.8 million, up 0.8% year-over-year, driven by DEXTENZA sales.

  • Net loss for Q1 2026 was $(88.6) million, or $(0.40) per share, reflecting increased R&D and SG&A expenses.

  • Research and development expenses rose to $66.2 million from $42.9 million year-over-year, mainly due to clinical trial progression.

  • Weighted average shares outstanding increased to 224.1 million from 169.4 million year-over-year.

Outlook and guidance

  • NDA submission for AXPAXLI in wet AMD planned based on SOL-1 week 52 data, leveraging the 505(b)(2) pathway for a potentially shortened review timeline.

  • SOL-R topline data guidance accelerated to Q1 2027 due to rapid enrollment.

  • Investor Day scheduled for June 17, 2026, to provide regulatory, program, and commercialization updates.

  • Cash runway projected into 2028, excluding full commercialization expenses for AXPAXLI.

  • Expect continued increases in R&D, SG&A, and pre-commercialization expenses for AXPAXLI and ongoing trials.

AXPAXLI 505(b)(2) pathway and review timeline
SOL-R screening phase and de-risking strategy
Cash runway and AXPAXLI commercialization costs
FDA single trial framework impact on NDA timing
Clinical significance of SOL-X crossover data
Rationale for broad diabetic retinopathy labeling
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Ocular Therapeutix earnings date

Logotype for Ocular Therapeutix Inc
Bank of America Global Healthcare Conference 202612 May, 2026
Ocular Therapeutix
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Ocular Therapeutix earnings date

Logotype for Ocular Therapeutix Inc
Bank of America Global Healthcare Conference 202612 May, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Explore our global coverage